These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
310 related items for PubMed ID: 27066956
21. Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation. Steppich B, Dobler F, Brendel LC, Hessling G, Braun SL, Steinsiek AL, Deisenhofer I, Hyseni A, Roest M, Ott I. J Thromb Thrombolysis; 2017 May; 43(4):490-497. PubMed ID: 28316004 [Abstract] [Full Text] [Related]
22. Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study. Liu Z, Xie Q, Zhang H, Mu G, Zhou S, Wang Z, Jiang J, Xiang Q, Cui Y. Am J Cardiovasc Drugs; 2021 Nov; 21(6):669-679. PubMed ID: 34142346 [Abstract] [Full Text] [Related]
23. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Barrett YC, Wang Z, Frost C, Shenker A. Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714 [Abstract] [Full Text] [Related]
25. Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7). Suzuki S, Morishima Y, Takita A, Otsuka T, Yagi N, Arita T, Yamashita T. Heart Vessels; 2020 Mar; 35(3):409-416. PubMed ID: 31522245 [Abstract] [Full Text] [Related]
26. Impact of rivaroxaban on point-of-care assays. Fontana P, Alberio L, Angelillo-Scherrer A, Asmis LM, Korte W, Mendez A, Schmid P, Stricker H, Studt JD, Tsakiris DA, Wuillemin WA, Nagler M. Thromb Res; 2017 May; 153():65-70. PubMed ID: 28343143 [Abstract] [Full Text] [Related]
28. Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban. Nakano Y, Kondo T, Osanai H, Murase Y, Nakashima Y, Asano H, Ajioka M, Sakai K, Inden Y, Murohara T. J Cardiol; 2015 Mar; 65(3):185-90. PubMed ID: 25192594 [Abstract] [Full Text] [Related]
29. Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population. Kitagawa F, Ishii J, Hiramitsu S, Takahashi H, Okuyama R, Kawai H, Muramatsu T, Harada M, Motoyama S, Naruse H, Matsui S, Sarai M, Hayashi M, Watanabe E, Izawa H, Ozaki Y. Heart Vessels; 2017 May; 32(5):609-617. PubMed ID: 27796530 [Abstract] [Full Text] [Related]
30. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution. Park SH, Seo YH, Park PW, Kim KH, Seo JY, Lee HT, Kwoun WJ, Ahn JY. J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622 [Abstract] [Full Text] [Related]
31. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level? Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM. Ann Pharmacother; 2015 Jul; 49(7):777-83. PubMed ID: 25855705 [Abstract] [Full Text] [Related]
32. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects. Moore KT, Byra W, Vaidyanathan S, Natarajan J, Ariyawansa J, Salih H, Turner KC. Br J Clin Pharmacol; 2015 Jun; 79(6):907-17. PubMed ID: 25475601 [Abstract] [Full Text] [Related]
33. Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study. Samoš M, Bolek T, Stančiaková L, Škorňová I, Bánovčin P, Kovář F, Staško J, Galajda P, Kubisz P, Mokáň M. Blood Coagul Fibrinolysis; 2018 Jun; 29(4):369-373. PubMed ID: 29538002 [Abstract] [Full Text] [Related]
34. Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay. He L, Kochan J, Lin M, Vandell A, Brown K, Depasse F. Thromb Res; 2017 Jul; 155():121-127. PubMed ID: 28535438 [Abstract] [Full Text] [Related]
35. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Ebner M, Birschmann I, Peter A, Spencer C, Härtig F, Kuhn J, Blumenstock G, Zuern CS, Ziemann U, Poli S. Crit Care; 2017 Feb 15; 21(1):32. PubMed ID: 28196509 [Abstract] [Full Text] [Related]
36. Anti-Factor Xa Activity of Standard and Japan-Specific Doses of Rivaroxaban in Thai Patients With Non-Valvular Atrial Fibrillation. Wongcharoen W, Pacharasupa P, Norasetthada L, Gunaparn S, Phrommintikul A. Circ J; 2020 Jun 25; 84(7):1075-1082. PubMed ID: 32461505 [Abstract] [Full Text] [Related]
37. Laboratory monitoring of rivaroxaban and assessment of its bleeding risk. Zhang Y, Qian Q, Qian G, Sun G. Br J Biomed Sci; 2016 Jul 25; 73(3):134-139. PubMed ID: 27400196 [Abstract] [Full Text] [Related]
38. Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation. Königsbrügge O, Weigel G, Quehenberger P, Pabinger I, Ay C. Clin Exp Med; 2018 Aug 25; 18(3):325-336. PubMed ID: 29417256 [Abstract] [Full Text] [Related]
39. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation. Nakagawa J, Kinjo T, Iizuka M, Ueno K, Tomita H, Niioka T. Basic Clin Pharmacol Toxicol; 2021 Feb 25; 128(2):297-304. PubMed ID: 32920985 [Abstract] [Full Text] [Related]
40. Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats. Dixon-Jimenez AC, Brainard BM, Brooks MB, Nie B, Arnold RD, Loper D, Abrams JC, Rapoport GS. J Vet Emerg Crit Care (San Antonio); 2016 Sep 25; 26(5):619-29. PubMed ID: 27599304 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]